Pediatric Nephrology

, Volume 29, Issue 1, pp 149–153 | Cite as

Eculizumab long-term therapy for pediatric renal transplant in aHUS with CFH/CFHR1 hybrid gene

  • Elena Román-Ortiz
  • Santiago Mendizabal Oteiza
  • Sheila Pinto
  • Margarita López-Trascasa
  • Pilar Sánchez-Corral
  • Santiago Rodríguez de Cordoba
Brief Report



Atypical hemolytic uremic syndrome (aHUS) is a form of thrombotic microangiopathy (TMA) caused by dysregulation of the complement system. Outcomes of kidney transplantation are poor owing to aHUS recurrence and loss of graft. Patients carrying CFH mutations or CFH/CFHR1 hybrid genes present a very high risk of recurrence despite preventive plasmapheresis. Evaluation of recent data suggests that prophylactic eculizumab pretransplant might be the preferred therapy if available.


We report 3-year follow-up data in a 9-year-old boy with aHUS and successful renal transplant treated with prophylactic eculizumab without recurrence. He presented with aHUS at age 3, irreversible renal failure and uncontrolled severe hypertension with concentric left ventricular hypertrophy, recurrent acute pulmonary edema, and congestive heart failure despite five hypotensive agents and bilateral nephrectomy. Complement analysis demonstrated the presence of a CFH/CFHR1 hybrid gene inherited from his mother and a SNP risk CFH haplotype inherited from his father. Kidney transplant was performed with prophylactic eculizumab and subsequent fortnightly administration. Three years post-transplant, graft function remains stable (serum creatinine 0.9 mg/dl), hypertension is controlled, no left ventricular hypertrophy, no opportunistic infections, and negative clinical chemistry parameters for hemolysis.


Eculizumab is a safe and effective therapy for preventing TMA recurrence and provides long-term graft function in aHUS with the CFH/CFHR1 hybrid gene.


Atypical hemolytic uremic syndrome Eculizumab Renal transplant recipient CFH/CFHR1 hybrid gene 



Atypical hemolytic uremic syndrome


Complement component 3


Complement component 5


Complement factor H


Complement factor I


Complement factor B


Membrane cofactor protein


CFH-related protein 1


Short consensus repeat domain


Thrombotic microangiopathy


Blood pressure



We thank Dr. Agustin Tortajada for his contribution to this work.

SRdeC is supported by the Spanish Ministerio de Economía y Competitividad [Ministry of Finance and Competition] (SAF2011-26583), the Comunidad de Madrid [Autonomous Region of Madrid] (S2010/BMD-2316), the European Union FP7 (EURENOMICS) and the Fundación Renal Iñigo Alvarez de Toledo.

PSC is supported by the Spanish Ministerio de Economía y Competitividad (PS09-00268), and the Comunidad de Madrid (S2010/BMD-2316).

MLT is supported by the Spanish Ministerio de Economía y Competitividad (PS09-00122), and the Comunidad de Madrid (S2010/BMD-2316).


SRdeC has received fees from Alexion Pharmaceuticals for invited lectures. This interaction has not influenced the results and interpretations in this manuscript. All other authors of this manuscript have no conflicts of interest to disclose, including sponsorship or funding arrangements relating to this research.

Supplementary material

467_2013_2591_MOESM1_ESM.png (329 kb)
Supplementary Fig. 1 Summary of the genetic data in the patient (H142) and their relatives. a The H142 pedigree. The members of the pedigree are identified, and for the affected individual H142 and the other carriers of the CFH/CFHR1 hybrid gene, the levels of total plasma FH and normal FH (402Y) are indicated. Notice that H142 also inherits an aHUS risk allele from his father. b Summary of the MLPA data. Graphs illustrate the number of copies of different exons in the CFH-CFHR1 region. Notice that levels of CFH exon 23, but not CFHR1 exon 6, are decreased in the patient and three of their relatives, indicating they are carriers of a CFH/CFHR1 hybrid gene. c Diagram of the FH molecule resulting from the CFH/CHFR1 hybrid gene. The circles indicate each of the 20 SCR domain units that compose FH. The locations of the four amino acid differences found are indicated. Notice that the two changes in SCRs 15 and 16 are rare polymorphisms with no functional relevance (see [10]). (PNG 328 kb)


  1. 1.
    Zuber J, Le Quintrect M, Sberro-Soussan R, Loirat C, Fremeaux-Bacchi V, Legendre C (2011) New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 7:23–25PubMedCrossRefGoogle Scholar
  2. 2.
    Zuber J, Le Quintrect M, Krid S, Bertoye C, Gueutin V, Lahoche A, Heune N, Ardissino G, Chatelet V, Noël LH, Hourmant M, Niaudet P, Fremeaux-Bacchi V, Rondeau A, Legendre C, Loirat C (2012) Eculizumab for atypical hemolytic syndrome recurrence in renal transplantation. Am J Transplant 12:3337–3354PubMedCrossRefGoogle Scholar
  3. 3.
    Sánchez-Corral P, González-Rubio C, Rodríguez de Córdoba S, López-Trascasa M (2004) Functional analysis in serum from atypical Hemolytic Uremic Syndrome patients reveals impaired protection of host cells associated with mutations in Factor H. Mol Immunol 41:81–84PubMedCrossRefGoogle Scholar
  4. 4.
    Rodríguez de Córdoba S, Tortajada A, Harris CL, Morgan P (2012) Complement dysregulation and disease: from genes and proteins to diagnostics and drugs. Immunobiology 217:1034–1046CrossRefGoogle Scholar
  5. 5.
    Venables JP, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P, Diaz-Torres ML, Sampson A, Mead P, Webb M, Pirson Y, Jackson MS, Hughes A, Wood KM, Goodship JA, Goodship TH (2006) Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 3:e431PubMedCrossRefGoogle Scholar
  6. 6.
    Chatelet V, Fremeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B (2009) Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 9:2644–2645PubMedCrossRefGoogle Scholar
  7. 7.
    Gruppo RA, Rother RP (2009) Eculizumab for congenital atypical hemolytic-uremic syndrome. N Eng J Med 360:544–546CrossRefGoogle Scholar
  8. 8.
    Krid S, Roumenina LT, Beury D, Charbit M, Boyer O, Frémeaux-Bacchi V, Niaudet P (2012) Renal Transplantation Under Prophylactic Eculizumab in Atypical Hemolytic Uremic Syndrome with CFH/CFHR1 Hybrid Protein. Am J Transplant 12:1938–1944PubMedCrossRefGoogle Scholar
  9. 9.
    Nester C, Stewart Z, Myers D (2011) Pre-emptive eculizumab and plasmapheresis for renal transplant in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 6:1488–1494PubMedCrossRefGoogle Scholar
  10. 10.
    Tortajada A, Pinto S, Martínez-Ara J, López-Trascasa M, Sánchez-Corral P, Rodríguez de Córdoba S (2012) Complement factor H variants I890 and L1007 while commonly associated with atypical haemolytic uremic syndrome are polymorphisms with no functional significance. Kidney Int 81:56–63PubMedCrossRefGoogle Scholar
  11. 11.
    Esparza-Gordillo E, Goicoechea de Jorge E, López-Trascasa M, Sánchez-Corral P, Rodríguez de Córdoba S (2005) Predisposition to atypical Hemolytic Uremic Syndrome involves the concurrence of different susceptibility alleles in the Regulators of Complement Activation gene cluster in 1q32. Hum Mol Genet 14:703–712PubMedCrossRefGoogle Scholar
  12. 12.
    Martinez-Barricarte R, Pianetti G, Gautard R, Misselwitz J, Strain L, Fremeaux-Bacchi V, Skerka C, Zipfel P, Goodship T, Noris M, Remuzzi G, Rodríguez de Córdoba S, on behalf of the European Working Party on the Genetics of HUS (2008) The complement factor H R1210C mutation is associated with atypical hemolytic uremic syndrome. J Am Soc Nephrol 19:639–646PubMedCrossRefGoogle Scholar
  13. 13.
    Zuber J, Fakouri F, Roumenia L, Loirat C, Fremeaux-Bacchi V (2012) Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 8:643–657PubMedCrossRefGoogle Scholar

Copyright information

© IPNA 2013

Authors and Affiliations

  • Elena Román-Ortiz
    • 1
  • Santiago Mendizabal Oteiza
    • 1
  • Sheila Pinto
    • 2
  • Margarita López-Trascasa
    • 3
  • Pilar Sánchez-Corral
    • 3
  • Santiago Rodríguez de Cordoba
    • 2
  1. 1.Pediatric Nephrology UnitHospital La FeValenciaSpain
  2. 2.Centro de Investigaciones Biológicas—Consejo Superior de Investigaciones Científicas (CIB-CSIC) [Centre for Biological Research—Spanish Scientific Research Council] and CIBER de Enfermedades Raras (CIBERER) [Centre for Biomedical Network Research on Rare Diseases]MadridSpain
  3. 3.Immunology Unit, CIBERER Research UnitHospital Universitario La PazMadridSpain

Personalised recommendations